Reneo Pharma Ltd
6
0
0
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
33.3%
2 terminated/withdrawn out of 6 trials
66.7%
-19.8% vs industry average
0%
0 trials in Phase 3/4
50%
2 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
An Open Label, Long Term Safety Study of REN001 in Primary Mitochondrial Myopathy Patients (Stride Ahead)
Role: lead
An Efficacy and Safety Study of 24 Week Treatment With Mavodelpar (REN001) in Primary Mitochondrial Myopathy Patients
Role: lead
A Prospective Study of the Disease Characteristics of Adult Patients With Long Chain Fatty Acid Oxidation Disorders
Role: lead
A Phase 1b Study of the Safety of REN001 in Patients With Fatty Acid Oxidation Disorders
Role: lead
A Study of the Safety of REN001 in Patients With McArdle Disease
Role: lead
A Study of the Safety of REN001 in Patients With Primary Mitochondrial Myopathy
Role: lead
All 6 trials loaded